Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 9
Submit an article Journal homepage
848
Views
8
CrossRef citations to date
0
Altmetric
Original Articles

Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia

Lydia L. Beniteza Michigan Medicine, Ann Arbor, MI, USA;b College of Pharmacy, University of Michigan, Ann Arbor, MI, USACorrespondence[email protected]
View further author information
,
Anthony J. Perissinottia Michigan Medicine, Ann Arbor, MI, USAView further author information
,
Caitlin R. Rauschc The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Jeff Klausd Barnes Jewish Hospital, St. Louis, MO, USAView further author information
,
Stephen Michael Clarke University of North Carolina Medical Center, Chapel Hill, NC, USAView further author information
,
Michael Filtzf Huntsman Cancer Institute, Salt Lake City, UT, USAView further author information
,
Kelley Ratermannf Huntsman Cancer Institute, Salt Lake City, UT, USAView further author information
,
Carissa Treptowg Department of Pharmacy, University of Rochester, Rochester, NY, USAView further author information
,
Shawn Griffinh Indiana University Health, Indianapolis, IN, USAView further author information
,
Marissa Olsond Barnes Jewish Hospital, St. Louis, MO, USAView further author information
,
Mallory Craind Barnes Jewish Hospital, St. Louis, MO, USAView further author information
,
Tapan Kadiac The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Kristen Pettita Michigan Medicine, Ann Arbor, MI, USAView further author information
,
Patrick W. Burkea Michigan Medicine, Ann Arbor, MI, USAView further author information
,
Dale L. Bixbya Michigan Medicine, Ann Arbor, MI, USAView further author information
&
Bernard L. Marinia Michigan Medicine, Ann Arbor, MI, USA;b College of Pharmacy, University of Michigan, Ann Arbor, MI, USAView further author information
 show all
Pages 2184-2192 | Received 14 Oct 2020, Accepted 08 Mar 2021, Published online: 08 Apr 2021

References

  • Cancer stat facts: leukemia - acute myeloid leukemia (AML). National Cancer Institute: surveillance, epidemiology, and end results program [Internet] [cited 2020 Mar 4]. Available from: https://seer.cancer.gov/statfacts/html/amyl.html.
  • Granfeldt Østgård LS, Medeiros BC, Sengeløv H, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol. 2015;33(31):3641–3649.
  • Kayser S, Döhner K, Krauter J, for the German-Austrian AMLSG, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2011;117(7):2137–2145.
  • Yates JW, Wallace HJ, Ellison RR, et al. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 1973;57(4):485–488.
  • Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684–2692.
  • Talati C, Goldberg AD, Przespolewski A, et al. Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy. Leuk Res. 2020;93:106367.
  • Vulaj V, Perissinotti AJ, Uebel JR, et al. The FOSSIL Study: FLAG or standard 7 + 3 induction therapy in secondary acute myeloid leukemia. Leuk Res. 2018;70:91–96.
  • Thomson Reuters M. RED Book drug references. Toronto (CA): IBM Corporation; 2019.
  • Vyxeos [package insert]. Palo Alto (CA): Jazz Pharmaceuticals; 2019.
  • Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
  • Montalban-Bravo G, Kanagal-Shamanna R, Class CA, et al. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol. 2020;95(6):612–622.
  • National Comprehensive Cancer Network. Acute Myeloid Leukemia (Version 1.2019). Available from: https://www.nccn.org/professionals/physician_gls/default.aspx on March 22, 2019.
  • Cheson BD, Bennett JM, Kopecky KJ, International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642–4649.
  • Sealed Envelope Ltd. 2012. Power calculator for binary outcome non-inferiority trial. [Online] [cited 2019 Jan 20]. Available from: https://www.sealedenvelope.com/power/binary-noninferior/.
  • Jaglal MV, Duong VH, Bello CM, et al. Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. Leuk Res. 2014;38(4):443–446.
  • Ball B, Komrokji RS, Adès L, et al. Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia. Blood Adv. 2018;2(16):2063–2071.
  • Talati C, Goldberg AD, Przespolewski A, et al. Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy. Blood. 2018;132(Supplement 1):665–665.
  • Gandhi V, Estey E, Keating MJ, et al. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993;11(1):116–124.
  • Gandhi V, Estey E, Du M, et al. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia. Clin Cancer Res. 1995;1(2):169–178.
  • Gandhi V, Kantarjian H, Faderl S, et al. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res. 2003;9(17):6335–6342.
  • Kadia TM, Jain P, Ravandi F, et al. TP53 mutations in newly diagnosed acute myeloid leukemia: clinicomolecular characteristics, response to therapy, and outcomes. Cancer. 2016;122(22):3484–3491.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.